SNHG6 and prostate carcinoma: The silencing of SNHG6 not only decreased cell proliferation, invasion, and migration, but also elevated the sensitivity of prostate cancer tissues to paclitaxel (PTX) confirming the role of SNHG6 in PTX resistance (Table 2).